Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P389: Efficacy and safety of ustekinumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: real clinical practiceECCO'21 Virtual
Year: 2021
Authors: Saiz Chumillas, R.M.(1);Alba Hernández, L.(1);Chivato Martín-Falquina, I.(1);Badia Aranda, E.(1);Arias García, M.L.(1);Sicilia Aladrén, B.(1);
(1)University Hospital of Burgos, IBD Deparment, Burgos, Spain
P390: Diverting Loop Ileostomy in Medically Refractory Crohn's ColitisECCO'21 Virtual
Year: 2021
Authors: Patel, P.(1);Wu, L.(2);
(1)Mid Central District Health Board, General Surgery, Palmerston North, New Zealand;(2)Waikato District Health Board, General Surgery, Waikato, New Zealand
P391: Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic reviewECCO'21 Virtual
Year: 2021
Authors: Verburgt, C.(1,2);Heutink, W.P.(3);Kuilboer, L.I.M.(1);Dickmann, J.D.(1);van Etten-Jamaludin, F.S.(4);Benninga, M.A.(1);de Jonge, W.J.(2,5);Van Limbergen, J.E.(1,2,6);Tabbers, M.M.(1);
(1)Emma Children’s Hospital- Amsterdam University Medical Centers, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands;(3)Wilhelmina Children’s Hospital- University Medical Center Utrecht, Department of Pediatrics, Utrecht, The Netherlands;(4)Amsterdam University Medical Centers, Research support- Medical library, Amsterdam, The Netherlands;(5)University of Bonn, Department of Surgery, Bonn, Germany;(6)Dalhousie University, Department of Pediatrics, Halifax, Canada
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility studyECCO'21 Virtual
Year: 2021
Authors: Van Erp, L.W.(1);Groenen, M.J.M.(1);Heida, W.(1);Wisse, J.(1);Roosenboom, B.(1);Wahab, P.J.(1);
(1)Rijnstate Hospital, Crohn & Colitis Centre- Department of Gastroenterology and Hepatology, Arnhem, The Netherlands
P393: Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims databaseECCO'21 Virtual
Year: 2021
Authors: Cazzetta, S.(1);Chen, G.(2);Pedarla, V.(3);Null, K.(4);Rana Khan, Q.(1);Schwartz, D.(5);
(1)Takeda Pharmaceuticals USA- Inc., Medical Affairs, Lexington, United States;(2)At the time of the study Takeda Pharmaceuticals USA- Inc., Clinical Pharmacology, Lexington, United States;(3)Statinmed Research, Research, Plano, United States;(4)Takeda Pharmaceuticals USA- Inc., Outcomes Research & Data Science, Lexington, United States;(5)Vanderbilt University Medical Center, Inflammatory Bowel Disease Center, Nashville, United States
P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);K. Weersma, R.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s diseaseECCO'21 Virtual
Year: 2021
Authors: Pai, R.(1);De Hertogh, G.(2);Reinisch, W.(3);Harpaz, N.(4);Feagan, B.(5);Agada, N.(6);Pollack, P.(6);Chan, L.S.(6);Protic, M.(6);Magro, F.(7);
(1)The Mayo Clinic, Laboratory Medicine/Pathology, Scottsdale, United States;(2)University Hospitals Leuven, Pathology, Leuven, Belgium;(3)Medical University Vienna, Internal Medicine, Vienna, Austria;(4)Icahn School of Medicine at Mount Sinai, Pathology and Medicine, New York, United States;(5)Robarts Clinical Trials Inc, Medicine, London, Canada;(6)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(7)University of Porto, Biomedicine, Porto, Portugal
P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life settingECCO'21 Virtual
Year: 2021
Authors: De Somer, T.(1);Deprez, N.(2);Baert, D.(1);Deceuninck, M.(3);Huys, I.(1);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten , E.(1);Vandervoort , J.(4);Van Heddegem, N.(1);Dewint, P.(1);
(1)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(2)Ghent University, Gastroenterology, Gent, Belgium;(3)AZ Sint-Vincentius, Gastroenterology, Deinze, Belgium;(4)OLV Ziekenhuis Aalst, Gastroenterology, Aalst, Belgium
P397: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labelingECCO'21 Virtual
Year: 2021
Authors: Iacucci, M.(1);Grisan, E.(2);Labarile, N.(1);Nardone, O.(1);Smith, S.C.(1);Jeffery, L.(1);Ghosh, S.(1);Buda, A.(3);
(1)University Hospitals NHS Foundation Trust and University of Birmingham- Birmingham- UK, Institute Translational of Medicine- Institute of Immunology and Immunotherapy and NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom;(2)School of Engineering- London South Bank University- London SE1 0AA- UK, Department of Engineering, London, United Kingdom;(3)S. Maria del Prato Hospital- Feltre- Italy, Department of Gastrointestinal Oncological Surgery-, Feltre, Italy
P398: Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with AnaemiaECCO'21 Virtual
Year: 2021
Authors: Bevers, N.(1);van de Vijver , E.(2);Aliu , A.(1);Rezazadeh Ardabili , A.(3);Rosias , P.(1);Busari , J.(4);Stapelbroek , J.(5);Bertrams , I.(6); van der Feen , C.(7);Oudshoorn , A.(8);Teklenburg , S.(9);Escher , J.(10);Vande Velde , S.(11);Winkens , B.(12);Raijmakers , M.(13);Vreugdenhil , A.(14); Pierik , M.(3);van Rheenen , P.(15);
(1)Zuyderland Medical Centre, Paediatrics, Heerlen, The Netherlands;(2)University Hospital Antwerp, Paediatric Gastroenterology- Hepatology- and Nutrition, Edegem, Belgium;(3)Maastricht University Medical Centre, Gastroenterology and Hepatology, Maastricht, The Netherlands;(4)Dr. Horacio E. Oduber Hospital, General Paediatrics and Adolescent care, Oranjestad, Aruba;(5)Catharina Hospital, Paediatrics, Eindhoven, The Netherlands;(6)Maxima Medical Centre, Paediatrics, Veldhoven, The Netherlands;(7)Jeroen Bosch Hospital, Paediatrics, 's-Hertogenbosch, The Netherlands;(8)Gelre Hospital, Paediatrics, Apeldoorn, The Netherlands;(9)Isala Clinics, Paediatrics, Zwolle, The Netherlands;(10)Erasmus Medical Centre, Paediatric Gastroenterology- Hepatology- and Nutrition, Rotterdam, The Netherlands;(11)University Hospital Ghent, Internal Medicine and Paediatrics, Ghent, Belgium;(12)Maastricht University, Methodology and Statistics, Maastricht, The Netherlands;(13)Zuyderland Medical Centre, Clinical Chemistry and Hematology, Heerlen, The Netherlands;(14)Maastricht University Medical Centre, Paediatric Gastroenterology and Hepatology, Maastricht, The Netherlands;(15)University Medical Centre Groningen, Paediatric Gastroenterology- Hepatology- and Nutrition, Groningen, The Netherlands; Popeye Study
P399: Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre studyECCO'21 Virtual
Year: 2021
Authors: De Gregorio, M.(1,2);Lee, T.(1);Krishnaprasad, K.(1,3);Amos, G.(4,5);An, Y.K.(4,6);Bastian-Jordan, M.(4,5);Begun, J.(6,7);Borok, N.(8,9);Brown, D.J.M.(10);Cheung, W.(11);Connor, S.(12,13,14);Gerstenmaier, J.(11);Gilbert, L.E.(15);Gilmore, R.(16);Gu, B.(12,14,17);Kutaiba, N.(18,19);Lee, A.(20,21);Mahy, G.(22);Srinivasan, A.(16,23,24);Thin, L.(25,26);Thompson, A.(1,2);Welman, C.J.(27);Yong, E.X.(28);De Cruz, P.(2,16);van Langenberg, D.(23,24);Sparrow co-lead senior author, M.(15,24);Ding, N.S.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia;(2)University of Melbourne, Medicine, Parkville, Australia;(3)QIMR Berghofer Medical Research Institute, Gut Health Lab, Brisbane, Australia;(4)University of Queensland, Medicine, St Lucia, Australia;(5)Queensland X-ray, Medical Imaging, Brisbane, Australia;(6)Mater Hospital Brisbane, Gastroenterology, South Brisbane, Australia;(7)University of Queensland, Mater Research Institute, St Lucia, Australia;(8)Liverpool Hospital, Medical Imaging, Liverpool, Australia;(9)South Western Sydney Local Health District, Medicine, Liverpool, Australia;(10)Townsville University Hospital, Medical Imaging, Douglas, Australia;(11)Alfred Health, Medical Imaging, Melbourne, Australia;(12)Liverpool Hospital, Gastroenterology and Hepatology, Liverpool, Australia;(13)Ingham Institute for Applied Medical Research, Medicine, Liverpool, Australia;(14)University of New South Wales, South Western Sydney Clinical School, Sydney, Australia;(15)Alfred Health, Gastroenterology, Melbourne, Australia;(16)Austin Health, Gastroenterology, Heidelberg, Australia;(17)Royal Prince Alfred Hospital, Gastroenterology and Hepatology, Camperdown, Australia;(18)Austin Health, Radiology, Heidelberg, Australia;(19)Eastern Health, Radiology, Box Hill, Australia;(20)Imaging Associates Eastern Health, Medical Imaging, Melbourne, Australia;(21)Peter MacCallum Cancer Centre, Cancer Imaging, Melbourne, Australia;(22)Townsville University Hospital, Gastroenterology, Douglas, Australia;(23)Eastern Health, Gastroenterology, Box Hill, Australia;(24)Monash University, Medicine, Clayton, Australia;(25)Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia;(26)University of Western Australia, School of Medicine and Pharmacology, Crawley, Australia;(27)Fiona Stanley Hospital, Medical Imaging, Murdoch, Australia;(28)St Vincent's Hospital Melbourne, Medical Imaging, Fitzroy, Australia; FISCAL
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patientsECCO'21 Virtual
Year: 2021
Authors: Les, A.(1);Iacob, R.(1);Cotruta, B.(1);Saizu, R.(1);Gheorghe, L.(1);Gheorghe, C.(1);
(1)Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort studyECCO'21 Virtual
Year: 2021
Authors: Lamb, C.A.(1,2);Sebastian, S.(3,4);Kent, A.J.(5);Segal, J.P.(6);Gonzalez, H.A.(3,4);Brookes, M.J.(7,8);Mehta, S.J.(9);Subramanian, S.(10,11);Bhala, N.(12,13);Hicks, L.C.(6);Conley, T.E.(10);Patel, K.V.(14);Walker, G.J.(15);Kennedy, N.A.(16,17);
(1)Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom;(2)Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom;(3)Hull University Teaching Hospitals NHS Trust, Department of Gastroenterology, Hull, United Kingdom;(4)University of Hull, Faculty of Health Sciences, Hull, United Kingdom;(5)King’s College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(6)Imperial College Healthcare NHS Trust, Department of Gastroenterology, London, United Kingdom;(7)Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(8)University of Wolverhampton, Research Institute in Healthcare Science, Wolverhampton, United Kingdom;(9)University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(10)Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Gastroenterology, Liverpool, United Kingdom;(11)Institute of Translational Medicine, Cellular and Molecular Physiology, Liverpool, United Kingdom;(12)Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom;(13)University of Birmingham, Institute of Applied Health Research, Birmingham, United Kingdom;(14)St George’s University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(15)Torbay and South Devon NHS Foundation Trust, Department of Gastroenterology, Torquay, United Kingdom;(16)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(17)University of Exeter, Exeter IBD Research Group, Exeter, United Kingdom; PREPARE-IBD Study Group
P402: Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?ECCO'21 Virtual
Year: 2021
Authors: Phillips, G.(1);Moore-Gillan, C.(1);Mohamed, Z.(1);Mikin, P.(1);Peake, S.(1);Hicks, L.(1);
(1)Imperial College London NHS Trust, Gastroenterology, London, United Kingdom
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.ECCO'21 Virtual
Year: 2021
Authors: Ferreiro Iglesias, R.(1);Hernández Camba, A.(2);Saldaña, R.(3);Rodríguez-Lago, I.(4);Zabana, Y.(5);Barreiro-de Acosta , M.(1);
(1)Servicio de Gastroenterología. Hospital Clínico Universitario de Santiago. Fundación Instituto de Investigación Sanitaria de Santiago de Compostela IDIS-, Gastroenterology Department, Santiago, Spain;(2)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Department, Tenerife, Spain;(3)ACCU Spain, Managing Director, Madrid, Spain;(4)Hospital Universitario de Galdakao, Gastroenterology Department, Bilbao, Spain;(5)Hospital Universitari Mútua de Terrassa. Centro Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Barcelona, Spain; On behalf of Young Group of GETECCU and ACCU
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in GermanyECCO'21 Virtual
Year: 2021
Authors: Picker, N.(1);Bokemeyer, B.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
(1)Ingress Health, HWM GmbH, Wismar, Germany;(2)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Galapagos, Nv, Mechelen, Belgium
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patientsECCO'21 Virtual
Year: 2021
Authors: Thomas, D.(1);Compernolle, G.(1);Guedelha Sabino, J.P.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Declerck, P.(1);
(1)KU Leuven, Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Chronic Diseases- Metabolism and Ageing, Leuven, Belgium
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countriesECCO'21 Virtual
Year: 2021
Authors: Kopylov, U.(1);Burisch , J.(2); Ben-Horin , S.(1);Braegger, F.(3);Fernández-Nistal , A.(4);Lara, N.(5);Vavricka , S.(6,7);
(1)Gastroenterology Institute- Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv, Israel;(2)Hvidvore University Hospital, Gastrounit- medical division, Hvidvore, Denmark;(3)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Zürich, Switzerland;(4)Takeda Farmacéutica España S.A., Medical Department, Madrid, Spain;(5)IQVIA, Real World Evidence Solutions, Barcelona, Spain;(6)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(7)Center for Gastroenterology und Hepatology AG, Center for Gastroenterology und Hepatology AG, Zürich, Switzerland
P407: Thiopurines: use them or lose them? Results of an international surveyECCO'21 Virtual
Year: 2021
Authors: Sousa, P.C.(1);Ministro, P.(2);Armuzzi, A.(3,4);Dignass, A.(5);Høivik, M.L.(6);Magro, F.(7,8,9);
(1)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(2)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(3)Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(4)Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(5)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt/Main, Germany;(6)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(7)Unit of Pharmacology and Therapeutics- University of Porto, Department of Biomedicine, Oporto, Portugal;(8)Centre for Drug Discovery and Innovative Medicines, MedInUP, Oporto, Portugal;(9)São João University Hospital, Department of Gastroenterology, Oporto, Portugal
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical SignificanceECCO'21 Virtual
Year: 2021
Authors: Doherty, J.(1);Varley, R.(1);Healy, M.(2);Dunne, C.(1);Mac Carthy, F.(1);McKiernan, S.(1);Hartery, K.(1);Kevans, D.(1);
(1)St James Hospital, Department of Gastroenterology, Dublin 8, Ireland;(2)St James Hospital, Department of Biochemistry, Dublin 8, Ireland